Impact of tislelizumab combined with albumin-bound paclitaxel and carboplatin on intestinal flora and gastrointestinal toxicities in advanced lung cancer.

Abstract

To evaluate the impact of tislelizumab combined with albumin-bound paclitaxel and carboplatin on intestinal flora and gastrointestinal toxicities in advanced lung cancer patients. A retrospective study of 431 patients (control group: albumin-bound paclitaxel + carboplatin; study group: Tislelizumab + albumin-bound paclitaxel + carboplatin). Intestinal micro biota, tumor markers, treatment efficacy and gastrointestinal adverse reactions were compared. The study group showed lower levels of pathogenic bacteria and higher levels of beneficial bacteria. The study group also had higher objective response rate (71.81%) and disease control rate (92.02%). No significant difference in gastrointestinal toxicities was observed. The combination therapy enhances treatment efficacy and reduces gastrointestinal toxicities.